GlobalData on MSN14h
Endeavor doses first subject in Phase IIb trial of ENV-101 for IPF treatment
Endeavor BioMedicines has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial in Australia, assessing the efficacy and safety of ENV-101 (taladegib), an investigational drug for ...
Novel nano-vaccine administered as nasal spray found to be effective against all major COVID-19 variants
Researchers at Tel Aviv University have developed an effective, inexpensive, and simple COVID-19 vaccine that can be stored ...